poietic stem cell transplantation; outcomes Cardiac complications following high-dose therapy and hematopoietic stem cell transplantation (HSCT) are relatively uncommon (5-10%), but have been well documented. 1 Congestive heart failure or pancarditis are late cardiac sequelae of HSCT and result from radiation injury and/or exposure to cardiotoxic chemotherapeutic agents used both in the initial treatment of malignancy and in the conditioning regimen. [2] [3] [4] Acute cardiac toxicities occurring during conditioning and in the immediate post transplant period include cyclophosphamide-induced acute cardiomyopathy or hemorrhagic pericarditis, 2 thiotepa-related acute myocarditis, 4 and bradyarrhythmias during the infusion of progenitor cells cryopreserved with dimethylsulfoxide (DMSO). 5 Although cardiac arrhythmias have been documented in several series, [2] [3] [4] the incidence, risk factors, and outcomes of this form of cardiac toxicity are unknown. We, therefore, conducted a retrospective singlecenter analysis in a large cohort of transplant patients, in order to better define characteristics of post transplant cardiac arrhythmias.
Materials and methods
Patients with peritransplant supraventricular tachyarrhythmias (SVTA) were identified through a bone marrow transplant inpatient pharmacy computerized search over a 6-year period, using the keywords intravenous amiodarone or diltiazem. These two drugs are used as first-line therapy for SVTA in the transplant unit. Patients who received these drugs during nontransplant admissions were excluded from the analysis. Medical records were reviewed and epidemiological information, prior cancer treatment, pretransplant evaluation, transplant characteristics, complications and outcomes were captured on specifically designed case report forms.
Statistical analyses were performed using STATA v.7 (SAS Institute, Cary, NC, USA), and results are reported as medians or proportion. Logistic regression analysis was used to model the probability of experiencing cardiac arrhythmia as a function of various prognostic covariates, with independent predictors reported as odds ratios (OR) with approximate 95% confidence intervals. Testing was performed at a significance level of 0.05.
Results

Patient characteristics
Between January 1996 and June 2002, 1465 patients underwent HSCT at Washington University in St Louis.
With our screening method, 2095 administrations of intravenous diltiazem and/or amiodarone for 136 patients were identified. A total of 76 patients were excluded because administration of the drugs occurred during nontransplant hospitalizations. A total of 60 patients (4.1%) received amiodarone or diltiazem in the peritransplant period, and complete medical records were available for review in 57.
Arrhythmias were observed in 7.6% of autografted patients and 2.5% of recipients of allogeneic transplants, 12% of patients with non-Hodgkin's lymphoma (NHL), 4% multiple myeloma (MM), 3% acute myeloid leukemia (AML), 3% breast cancer (BC), 2% chronic myeloid leukemia (CML), 2% myelodysplasia (MDS), 1% acute lymphoid leukemia (ALL), and 1% Hodgkin's disease (HD) (Figure 1 ). Table 1 summarizes characteristics of patients who developed SVTA. The median age was 59 years (range, 19-70). Patients were transplanted for lymphoma (n ¼ 31, 54%), leukemia (n ¼ 10, 18%), breast cancer (n ¼ 8, 14%), MM (n ¼ 7, 12%), or MDS (n ¼ 1, 2%). A total of 43 patients (75%) received autologous HSCT. Six (11%) were allografted from a matched sibling and eight (14%) from a matched unrelated donor. Transplant conditioning regimens included: fractionated total-body irradiation/cyclophosphamide/etoposide (TBI/ Cy/VP16: n ¼ 26, 46%), BCNU/VP16/cytosine arabinoside/melphalan (BEAM: n ¼ 14, 25%), melphalan/VP16/ carboplatin (MEC: n ¼ 7, 12%), melphalan (n ¼ 4, 7%), BCNU/VP16/cytosine arabinoside/Cy (BEAC: n ¼ 4, 7%), busulfan/Cy (Bu/Cy: n ¼ 1, 2%), and Cy /CDDP/BCNU (n ¼ 1, 2%).
Characteristics of SVTA
SVTA occurred at a median of 6 days (range, day 1-26) after transplantation, and presented as atrial fibrillation (n ¼ 35), flutter (n ¼ 7), both (n ¼ 10), or supraventricular tachycardia (n ¼ 5). The median electronically recorded heart rate at the onset of arrhythmia was 155 bpm. Patients were symptomatic and hemodynamic compromise was precipitated by the arrhythmias in 24 patients (42%), necessitating intravenous vasopressors in 17 (30%) and/or emergent electrical cardioversion in 16 (28%). A total of 30 patients received amiodarone (53%), 41 received diltiazem (72%), and 82% received either drug in combination with other anti-arrhythmic agents such as beta-blockers (n ¼ 25, 44%), or digoxin (n ¼ 30, 53%). All patients, except two, successfully converted to normal sinus rhythm (NSR) at a median of 3 days (range, 0-8 days) after the onset of arrhythmia. One patient expired before converting to NSR and one patient had persistent, but rate-controlled atrial fibrillation at the time of discharge. In all, 28 patients (49%) had a relapse of the arrhythmia at a median of 3 days after conversion to NSR (range, 0-46 days), of which 20 were still receiving anti-arrhythmics. Relapsed arrhythmia was successfully managed by continuation of the same drugs administered at higher doses (n ¼ 17), the addition of another agent (n ¼ 13), or reinstitution of the previously administered anti-arrhythmic (n ¼ 4). Arrhythmia characteristics are summarized in Table 2 .
Predisposing factors
Cardiac function is assessed for all transplant candidates by a cardiac nuclear (MUGA) scan and ECG. Echocardiography is not part of the standard pre-transplant work-up. Pre-transplant cardiac function was normal (450%) in all patients except three (5%), who had a left ventricular ejection fraction of less than 45% as measured by MUGA scan. A total of 17 patients (30%) had well-controlled preexisting cardiac conditions that did not exclude them from transplantation: coronary artery disease (n ¼ 5), arrhythmia (n ¼ 10), congestive heart failure (n ¼ 3), and/or prior cardiac surgery (n ¼ 8). Pre-transplant prolonged QTc interval (40.44 s) was observed in 15 patients (26%). Three patients had prior mediastinal radiotherapy. In total, 89% of patients received an anthracycline at a median of 5 months (range 1-128 months) prior to conditioning. On the day the arrhythmia began, 58% of patients (n ¼ 33) had a neutropenic fever. Serum chemistries were within normal limits except for in three patients (5%), who had a low serum potassium (o3 mEq/l) and five (9%) who had a low serum magnesium (o1.3 mEq/l). Complete blood counts were monitored daily, and patients were transfused to maintain the hemoglobin above 8.5 g/dl.
In order to determine the etiology of the arrhythmia, studies were obtained to rule out hyperthyroidism (n ¼ 33, 58%), myocardial infarction (n ¼ 43, 75%), and pulmonary embolus (n ¼ 15, 26%). Two patients had increased serum troponin levels (41.4 ng/ml) in the absence of clinical or ECG evidence of myocardial infarction, 12 patients had low TSH levels (o0.5 mU/ml) consistent with euthyroid sick syndrome, and pulmonary embolism was diagnosed in one patient (1.8%) using perfusion/ventilation scan or spiral CT.
Risk factor analysis for patients with NHL
In order to identify risk factors, the 30 patients with NHL who developed post-transplant SVTA were compared to 219 nonmatched NHL patients autografted during the same period and who did not have post transplant SVTA ( Table 3) . Arrhythmia patients were older (61 vs 52, P ¼ 0.006) and were more likely to have had a pre-existing cardiac condition (47 vs 12%, Po0.001). Pre-transplant cardiac testing (QTc, EF) was not predictive of posttransplant arrhythmia. There were no differences in disease characteristics (histology, stage at diagnosis), cumulative doses of adriamycin, or interval from the last dose of chemotherapy to transplant between arrhythmia patients and controls (data not shown). However, arrhythmia patients received more cycles of chemotherapy (10 vs 8 cycles, P ¼ 0.05), with rituximab often included in the pretransplant salvage regimen (60 vs 37%, P ¼ 0.02). Patients in the arrhythmia group more often received BEAM for conditioning (47 vs 25%, P ¼ 0.01). Exposure to DMSO during stem cell infusion, indirectly measured by the Table 2 Arrhythmia characteristics (n ¼ 57) 
Outcomes of patients with SVTA
Patients with respiratory failure requiring intubation and mechanical ventilation were analyzed separately Those patients have very poor outcomes and high mortality rates. 6-9. Indeed, there were no survivors among the 17 (30%) SVTA patients who were intubated and mechanically ventilated. Arrhythmias antedated intubation in nine patients and occurred after intubation in eight. All except one patient converted to NSR, but adverse cardiac events subsequently developed in seven patients: congestive heart failure (n ¼ 3), myocardial infarction (n ¼ 1), or cardiac arrest (n ¼ 3). Only three patients in this group had underlying pre-transplant cardiac disease. Causes of death are summarized in Table 4 .
In the majority of patients (n ¼ 40, 70%), SVTA occurred during moderate post-transplant complications such as neutropenic fevers, mucositis, or neutropenic colitis. Microbiologically documented sepsis was observed in six patients, five had renal failure (serum creatinine 42), and two had biochemical evidence of liver dysfunction (liver enzymes 43 Â upper limit of normal). Atrial fibrillation/ flutter occurred in 37 of those patients (93%) and supraventricular tachycardia in three. All but one patient converted to NSR, but subsequent cardiovascular adverse events were observed in three patients: myocardial infarction (n ¼ 1), cerebrovascular accident precipitated by atrial fibrillation (n ¼ 1), and cardiopulmonary arrest (n ¼ 1). A total of 13 patients (33%) had a pre-transplant history of cardiac disease. Median day of discharge from the hospital was 17 days (range, 11-53), and only one patient had a prolonged transplant hospitalization (430 days) due to recurrent atrial fibrillation. In particular, NHL patients with SVTA had prolonged hospitalizations (P ¼ 0.02) and a higher day-30 mortality (P ¼ 0.01). In all, 23 patients are alive with a median follow-up of 188 days post-HSCT, and relapses of the arrhythmia were not observed. Relapsed disease and infections were the most common causes of death in this group of patients (Table 4) .
Discussion
In this single-center study, we sought to determine the incidence, characteristics, risk factors and outcomes of post-transplant SVTA. Patients were identified through a computerized search of the BMT in-patient pharmacy database using the keywords amiodarone and diltiazem. This approach was considered appropriate, as these two drugs are agents routinely used as first-line therapy in our unit to manage SVTA. Our incidence of 4.1% may be an underestimation of the true incidence since cardiac monitors are not routinely used during the transplant hospitalization. Additionally, and by design, our screening method did not capture patients with transient cardiac rhythm disturbances that do not require therapeutic intervention, patients with bradyarrhythmias, arrhythmias occurring as late complication of transplantation, or the occasional cases treated with direct cardioversion. Thus, although we are confident that our data accurately reflect the incidence of clinically significant SVTA in the peritransplant period, the true incidence of those arrhythmias is likely to be somewhat higher. The incidence of SVTA at our center is comparable to that previously reported for general cardiac toxicity occurring post transplant. 1, 5, 10, 11 Cardiac arrhythmias manifested most frequently as atrial fibrillation/flutter (91%) and often required treatment with multiple anti-arrhythmic agents and aggressive interventions to maintain hemodynamic stability (30%). Conversion to normal sinus rhythm was achievable in the majority of patients with pharmacologic intervention alone, but nevertheless, a third of patients required electrical cardioversion. Although arrhythmia relapses were common (48%), ultimately all but one patient who did not have respiratory failure were discharged from the hospital in sinus rhythm.
Cardiac arrhythmias have been previously reported to occur after high-dose therapy and HSCT. One report describes the onset of early (day À1 to þ 12) post transplant paroxysmal atrial fibrillation after autologous HSCT in five patients conditioned with high-dose melphalan. All cases were treated with propanfenone and resolved within 72 h. 10 In one study analyzing 63 patients undergoing autologous HSCT, 11 one or more episodes of arrhythmia were observed in 21 patients, of whom only two required therapeutic intervention. The majority of these arrhythmias occurred during infusion of cyclophosphamide (sinus tachycardia, n ¼ 13) or DMSO cryopreserved bone marrow (sinus bradycardia, n ¼ 11). Only three cases of atrial arrhythmia and two ventricular extrasystoles Table 4 Causes of death (n ¼ 57) were observed independently of cyclophosphamide and DMSO. In another study from Finland, five cases of benign cardiac rhythm disturbances were observed among 45 allogeneic transplant recipients: 12 two ventricular extrasystoles, two atrial fibrillation or supraventricular tachycardia, and one ventricular tachyarrhythmia. In the largest retrospective review of general cardiac toxicities occurring in the acute phase of transplantation from University of Minnesota, 13 10 cases of arrhythmias occurring between days 0 and þ 79 were identified among 2821 HSCT recipients: six atrial fibrillation/flutter, two ventricular fibrillations, and two bradycardias leading to cardiac arrest. Finally, among 48 patients with NHL receiving high-dose chemotherapy with BEAC conditioning for autologous stem cell transplantation, atrial fibrillation was observed in one patient, while five developed acute heart failure.
14 To our knowledge, this is the first and the largest report specifically describing characteristics, outcomes, and risk factors for post transplant cardiac arrhythmias.
Risk factors for post transplant cardiac toxicity have been previously identified. Patients with low pre-transplant ejection fraction and female recipients of allogeneic HSCT are at risk for early thiotepa-induced congestive heart failure. Older age and a diagnosis of NHL were also identified as independent risk factors for heart failure after high-dose therapy and autologous HSCT. 15 In our study, patients with post transplant cardiac arrhythmias were relatively older (median age 59 years), and NHL was the most common underlying diagnosis (53%). The high proportion of NHL patients in the arrhythmia study group prompted us to analyze risk factors in this particular cohort of patients. Indeed, the NHL patients represent a rather homogenous group of patients with regards to pretransplant therapy, conditioning (TBI, BEAM or BEAC), and type of transplant (autologous HSCT). We observed no gender predominance, but older age and pre-existing cardiac condition were independent risk factors for the development of post-transplant cardiac arrhythmia.
In summary, post transplant SVTA are relatively uncommon, but clinically significant complications of hematopoietic stem cell transplantation. Patients with NHL appear to be at increased risk for SVTA, especially older patients and those with pre-existing cardiac disease. If future prospective studies confirm these observations, prophylactic therapy with amiodarone or a beta-blocker may be warranted in patients at high-risk for SVTA.
